[Diabetes mellitus and heart failure: epidemiology and therapy].
Diabetes mellitus and heart failure show a high coincidence, promote pathogenesis and worsen prognosis of each other. Currently, there are no prospective studies evaluating a specific antidiabetic or cardiologic therapy in diabetic patients with heart failure. Furthermore, a favorable effect of optimized glycemic control on the progression of heart failure has not been proven yet. Retrospective analyses indicate a rather positive effect of the insulin sensitizers metformin and glitazones and a neutral or rather negative effect of insulin and sulfonylureas in diabetic patients with heart failure. Up to now, due to missing prospective, controlled trials no evidence-based antidiabetic therapy can be recommended in diabetic heart failure patients.
Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Kerpener Strasse 62, 50937, Köln. roman.pfister@uk-koeln.de
Roman
R
Pfister
Erland
E
Erdmann
D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology*; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*
D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents